Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FACTs

Financiado

Cerrado

Fast Acting Virus Control Strategies for Production Animal Diseases

The objective of the FACTs project is to sign a term sheet with investors for ViroVet, an emerging Belgian biotech company, aimed at developing and introducing a disruptive treatment for bovine viral diarrhoea (BVD) in beef cattle... ver más

31/10/2015

ARATANA THERAPEUTI...

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ARATANA THERAPEUTICS NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2015-10-31

BIOTEC-5a-2014-1: SME boosting biotechnology-based in...

I+D

Cerrada hace 10 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ARATANA THERAPEUTICS NV

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BoVLP-BVD Development of Tagged DIVA Virus Like Particle polyantige... 71K€ Cerrado

BoVLP-BVD Tagged DIVA polyantigenic vaccine against Bovine Viral Dia... 2M€ Cerrado

DESARROLLO DE UNA VACUNA CONTRA LA MASTITIS B... DESARROLLO DE UNA VACUNA CONTRA LA MASTITIS BOVINA 473K€ Cerrado

NUEVO TRATAMIENTO DE LA ENFERMEDAD RESPIRATOR... NUEVO TRATAMIENTO DE LA ENFERMEDAD RESPIRATORIA EN BOVINO BA... 388K€ Cerrado

PDC2022-133314-I00 BIOSENSOR PORTATIL PARA ESTIMAR EL CONSUMO DE CALOSTRO PARA... 141K€ Cerrado

PID2019-107601RB-C33 BRUCELOSIS OVINA: VACUNAS SEGURAS Y ESTRATEGIAS DIVA FRENTE... 102K€ Cerrado

Duración del proyecto: 6 meses Fecha Inicio: 2015-04-08
Fecha Fin: 2015-10-31

Líder del proyecto

ARATANA THERAPEUTICS NV No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The objective of the FACTs project is to sign a term sheet with investors for ViroVet, an emerging Belgian biotech company, aimed at developing and introducing a disruptive treatment for bovine viral diarrhoea (BVD) in beef cattle. BVD is a globally endemic disease of cattle costing the industry billions of Euros every year in the form of increased mortality, decreased feed efficiency and increased susceptibility to secondary disease. Conventional BVD vaccines are unable to fully control the disease due to antigenic variability of the virus and inadequate host immune response to vaccination. BVD virus can infect calves in utero leading to persistently infected (PI) animals that are difficult to detect but that shed massive amounts of virus, resulting in continuous contamination of the herd. The product will initially be launched in the EU and US, with other large beef-producing markets, such as Brazil, also considered. It will be administered to cattle upon arrival at the feedlot or auction house, which is a time of high susceptibility to infection. The drug will prevent exposed animals from developing clinical disease and will reduce viral shedding by PI animals until they are identified and separated from the herd. The drug will be added to standard processing procedures to minimize labour time and cost. The BVD project is in TRL-6 stage and is predicted to reach market in 6-8 years’ time with peak sales of €150 million in the EU and US alone. Key opinion leaders (KOLs) are supportive of the product and a number of investors have expressed their interest. In Phase I, ViroVet will conduct market research and consult with KOLs in Europe and in other major beef markets to ensure successful introduction of the product. A comparative analysis of regulatory requirements will assist in the refinement of the business plan that will minimize time to market and maximize rapid return on investment. Contracts with investors will be finalized and a term sheet will be signed.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores